Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT01993732 Completed - Cancer Clinical Trials

Ovarian Tissue Cryopreservation in Females Undergoing Procedures That Will Potentially Lead To Loss of Ovarian Function

Start date: August 6, 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to retrieve and cryopreserve ovarian tissue from females undergoing a treatment that may lead to irreversible loss of ovarian function.

NCT ID: NCT01986426 Completed - Breast Cancer Clinical Trials

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Start date: November 2013
Phase: Phase 1
Study type: Interventional

The study will assess the safety, tolerability, PK and efficacy of different intra-tumoral dosing regimens of LTX-315; a lytic-peptide that induces long-term anti-cancer immune responses, as monotherapy or in combination with ipilimumab or pembrolizumab.

NCT ID: NCT01983332 Completed - Cancer Clinical Trials

Impact of MOHO on Therapists Working With Clients in Cancer Population

MDACC-MOHO
Start date: August 2013
Phase: N/A
Study type: Observational

The purpose of this study is to examine the impact of an introduction to the occupation-based theory (MOHO) on the clinical reasoning of therapists working with cancer clients.

NCT ID: NCT01980355 Completed - Cancer Clinical Trials

TXA Study in Major Oncologic Surgery

TXA
Start date: June 12, 2012
Phase: N/A
Study type: Interventional

Major surgery can result in blood loss that can require a blood transfusion during and/or after surgery. Tranexamic acid is a medication that was first introduced in the 1960s as a treatment for heavy menstrual bleeding. Over the past 20 years it has been used and studied in patients undergoing open-heart surgery, liver transplantation, and urologic surgery. We believe tranexamic acid may possibly decrease bleeding related to major surgery, resulting in reduced blood loss, lower blood transfusion rates, and possibly decreased hospital costs related to your surgical hospital stay. In this study, you will receive either the drug tranexamic acid or a placebo. The placebo looks like the tranexamic acid, but does not have any active ingredient in it. The treatment you get will be chosen by chance, like flipping a coin. You will have equal chance of being given the tranexamic acid or the placebo. In this study, both the tranexamic acid and the placebo are considered research.

NCT ID: NCT01979146 Completed - Cancer Clinical Trials

Cancer & Chemotherapy Symptom Management Using an Automated Telephone Reporting System

Start date: April 2001
Phase: N/A
Study type: Interventional

The purpose of this study was to test the efficacy of a computer-based automated symptom monitoring telephone system used by patients who received chemotherapy for their cancer to communicate unrelieved symptoms they experienced to their oncology providers.

NCT ID: NCT01976949 Completed - Clinical trials for Cancer Survivors With Clinically Significant Distress

Evaluation of a Social-networking Intervention to Reduce Cancer-related Distress

Start date: July 2009
Phase: N/A
Study type: Interventional

It is hypothesized that the treatment group will show greater improvements in quality of life and mood disturbance compared to the control group and that greater levels of engagement with the intervention materials will be associated with greater improvements in mood and quality of life.

NCT ID: NCT01973946 Completed - Cancer Clinical Trials

Cancer Symptom Monitoring Telephone System With Nurse Practitioner (NP) Follow up

Start date: September 2007
Phase: N/A
Study type: Interventional

The purpose of this prospective trial is to test a daily telephone based automated symptom monitoring and response system to track and further treat unrelieved symptoms for patients living at home during chemotherapy treatment as compared with usual care which consists of patients calling their oncology provider for symptom concerns.

NCT ID: NCT01970254 Completed - Cancer Clinical Trials

Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy

Start date: June 24, 2013
Phase:
Study type: Observational

This trial studies hepatitis B screening strategies of new cancer patients scheduled to undergo chemotherapy. Patients with cancer and hepatitis B virus infection are at risk of reactivation of infection after chemotherapy. Hepatitis B virus infection reactivation can be prevented by starting antivirals before chemotherapy in patients who are hepatitis B virus infection positive. Hepatitis B screening may help doctors prevent the reactivation of hepatitis B virus infection after chemotherapy.

NCT ID: NCT01969370 Completed - Cancer Clinical Trials

NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing

NCGENES
Start date: August 2012
Phase: N/A
Study type: Interventional

This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. This sub-project is investigating benefits and harms of providing WES diagnostic and different types of incidental findings to adult patients and parents of pediatric patients who undergo WES because they have symptoms suggesting genetic disease.

NCT ID: NCT01968798 Active, not recruiting - Cancer Clinical Trials

ASPREE Cancer Endpoints Study

ACES
Start date: September 2013
Phase: Phase 4
Study type: Interventional

The ASPREE Cancer Endpoint Study (ACES), an ancillary study of the ASPirin in the Prevention of Events in the Elderly (ASPREE) Study, will allow for the examination of the effect of daily low-dose aspirin (100 mg) compared to placebo, on specific DNA biomarkers and selected specific incident and recurrent cancer and metastases. The establishment of this ACES biobank will allow for the exploration of DNA-related molecular mechanisms of aspirin's protective effect against cancer, cancer associated mortality and metastases, using blood or saliva DNA specimens, urine, and tumor tissue.